These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26652959)

  • 21. The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation.
    Kearns B; Rafia R; Leaviss J; Preston L; Brazier JE; Palmer S; Ara R
    BMC Health Serv Res; 2017 Jan; 17(1):78. PubMed ID: 28118838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003-2013 and came closer to the population average].
    Brož J; Honěk P; Dušek L; Pavlík T; Kvapil M
    Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S14-20. PubMed ID: 26652960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Occupational tuberculosis in Slovakia and in the Czech Republic].
    Buchancová J; Svihrová V; Legáth L; Bátora I; Záborský T; Rozborilová E; Fenclová Z; Urban P; Zibolenová J; Osina O; Janoušek M; Hudečková H
    Epidemiol Mikrobiol Imunol; 2014 Sep; 63(3):200-5. PubMed ID: 25412484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment.
    Burke J; Kovacs B; Borton L; Sander S
    Postgrad Med; 2012 Mar; 124(2):77-91. PubMed ID: 22437218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of the burden of diabetes in Poland].
    Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of different approaches for estimation of prevalence of type 2 diabetes mellitus in the Czech Republic].
    S PHM; Škodová M; Kučová P; Votápková J
    Vnitr Lek; 2020; 66(5):69-71. PubMed ID: 32942873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of multiple sclerosis in the Czech Republic: the COMS study.
    Blahova Dusankova J; Kalincik T; Dolezal T; Kobelt G; Havrdova E
    Mult Scler; 2012 May; 18(5):662-8. PubMed ID: 21965424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of maternal mortality in the Czech Republic in 2000].
    Srp B; Velebil P
    Ceska Gynekol; 2002 Sep; 67(5):268-74. PubMed ID: 12434662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Polish Multicenter Study on Diabetes Epidemiology (PMSDE)--1998-2000].
    Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):751-8. PubMed ID: 11928582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience in data management of the clinical retrospective project in Czech and Slovak oncology centres (IKARUS Project)].
    Chroust K; Fínek J; Zemánek P; Brabec P; Dusek L
    Klin Onkol; 2009; 22(4):163-7. PubMed ID: 19731878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trend and factors associated with healthcare use and costs in type 2 diabetes mellitus: a decade experience of a universal health insurance program.
    Cheng JS; Tsai WC; Lin CL; Chen L; Lang HC; Hsieh HM; Shin SJ; Chen T; Huang CT; Hsu CC
    Med Care; 2015 Feb; 53(2):116-24. PubMed ID: 25517075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The costs of physical inactivity in the Czech Republic in 2008.
    Maresova K
    J Phys Act Health; 2014 Mar; 11(3):489-94. PubMed ID: 23416762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
    Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
    Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of the development of metformin and sulfonylurea prescriptions in the Czech Republic].
    Janíčková-Žďarská D; Honěk P; Dušek L; Pavlík T; Kvapil M
    Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S25-9. PubMed ID: 26652962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study.
    Johnson JA; Pohar SL; Majumdar SR
    Diabetes Care; 2006 Nov; 29(11):2403-8. PubMed ID: 17065675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data.
    Müller N; Heller T; Freitag MH; Gerste B; Haupt CM; Wolf G; Müller UA
    Diabet Med; 2015 Jul; 32(7):951-7. PubMed ID: 25781644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system.
    Bahia LR; Araujo DV; Schaan BD; Dib SA; Negrato CA; Leão MP; Ramos AJ; Forti AC; Gomes MB; Foss MC; Monteiro RA; Sartorelli D; Franco LJ
    Value Health; 2011; 14(5 Suppl 1):S137-40. PubMed ID: 21839888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs of dementia in the Czech Republic.
    Holmerová I; Hort J; Rusina R; Wimo A; Šteffl M
    Eur J Health Econ; 2017 Nov; 18(8):979-986. PubMed ID: 27785577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.